3 ‘Strong Buy’ Biotechs That Can Double In 2018

Here are three stocks that analysts say are primed for huge out-sized growth in the next 12 months. Biotech stocks often present intriguing investment opportunities- although the rewards can be quickly eradicated if key regulatory approvals are delayed or refused. To minimize the risk, we specifically searched for stocks with a high degree of confidence from top analysts.

In this case, we used the popular Trending Stocks tool to filter for best-rated stocks in the last week and with any market cap size. We crunched the data and pinpointed these three compelling stocks that are trending right now.

You can also see the average analyst price target and in green the upside percentage from the current share price. This is a crucial indicator of price potential over the next 12 months. All three stocks share a ‘Strong Buy’ analyst consensus rating.

Let’s delve deeper into why the Street is so bullish on these stocks now:

TG Therapeutics 

TG Therapeutics (Nasdaq:TGTX) is focused on the development of novel treatments for B-cell malignancies and autoimmune diseases. Following strong Q4 results, five-star HC Wainwright analyst Edward White ramped up his price target from $33 to $38 on March 8.

He explains: “We use the net present value of our revenue forecast through 2026, apply a 55% probability of success (POS) for ublituximab in CLL (Chronic Lymphocytic Leukemia), a 45% POS for umbralisib in CLL, and a 25% POS for both ublituximab and umbralisib in NHL (Non-Hodgkin Lymphoma), to arrive at our $38 price target.”

Bear in mind that so far White has struck gold with his TGTX recommendations. Across his 20 ratings on the stock he scored a 90% success rate and 44.4% average return. Meanwhile B.Riley FBR’s Madhu Kumar selects TGTX as an Out the Gate 2018 Pick, due to his “reasonable confidence in success in the Phase III UNITY-CLL trial, with interim data expected in 2Q18.”